A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4

A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4

The G protein–coupled CXC chemokine receptor 4 (CXCR4) is a candidate therapeutic target for tissue fibrosis. A fully human single-domain antibody-like scaffold i-body AD-114-PA600 (AD-114) with specific high binding affinity to CXCR4 has been developed. To define its renoprotective role, AD-114 was...

Full description

Bibliographic Details
Main Authors: Qinghua Cao, Chunling Huang, Hao Yi, Anthony J. Gill, Angela Chou, Michael Foley, Chris G. Hosking, Kevin K. Lim, Cristina F. Triffon, Ying Shi, Xin-Ming Chen, Carol A. Pollock
Format: Article
Language:English
Published: American Society for Clinical investigation 2022-02-01
Series:JCI Insight
Subjects:
Nephrology
Therapeutics
Online Access:https://doi.org/10.1172/jci.insight.143018

Internet

https://doi.org/10.1172/jci.insight.143018

Similar Items